Related Experiment Videos
[Effect of Complamin on fibrinolysis and platelet aggregation in the aged]
Insights
Complamin slightly reduced platelet aggregation in vivo but inhibited it in vitro. It also induced limited fibrinolysis, with variable patient responses and no significant effects after prolonged infusion.
Area of Science:
- Pharmacology
- Hematology
- Hemostasis
Context:
- Platelet aggregation and fibrinolysis are critical in hemostasis and thrombosis.
- Complamin (ியம்) is a vasoactive drug with potential effects on blood coagulation.
- Understanding Complamin's impact on platelet function and fibrinolytic activity is essential for its clinical application.
Purpose:
- To investigate the effects of various Complamin doses on platelet aggregation and blood fibrinolytic activity.
- To evaluate Complamin's in vitro impact on platelet aggregation.
- To assess changes following intravenous administration and prolonged infusion.
Summary:
- Intravenous Complamin showed minimal reduction in platelet aggregation in vivo.
- Complamin significantly inhibited adenosine diphosphate (ADP)- and collagen-induced platelet aggregation in vitro.
- Fibrinolytic activity was induced by Complamin, but its extent and duration varied among patients.
- Prolonged intravenous infusion of Complamin did not lead to significant modifications in the examined hemostatic parameters.
Impact:
- This study provides insights into Complamin's specific mechanisms affecting platelet function and fibrinolysis.
- Findings suggest Complamin may have a role in modulating thrombotic processes, particularly in vitro.
- The patient-dependent variability in fibrinolysis highlights the need for personalized treatment considerations.
- The lack of effect after prolonged infusion indicates potential limitations in its long-term therapeutic efficacy for hemostatic disorders.
Abstract:
Investigated were the behaviour of platelet aggregation and fibrinolytic activity of the blood, under the influence of different doses of Complamin, and its effect in vitro on platelet aggregation. We have shown that platelet aggregation diminished only slightly after intravenous injection of Complamin, but the ADP-and collagen-induced aggregation in vitro were inhibited. Except that, fibrinolytic activity in the blood had been induced, but the degree and continuance of fibrinolysis were limited depending on the patient. There was no significant modifications of examined tests after prolonged intravenous infusion of the drug.